Translumina

Executive Summary

Translumina is a German-based private medical device company that designs and manufactures interventional cardiovascular devices, including drug-eluting stents, drug-eluting balloons, and PTCA balloons. Founded in 2006, the company operates advanced manufacturing facilities in Germany, the Netherlands, and India, and serves over 60 countries. With a focus on coronary care, Translumina combines innovative technology with clinical excellence to deliver high-quality, cost-effective solutions. The company's global footprint and established product portfolio position it as a competitive player in the cardiovascular device market, though it remains privately held with limited public financial disclosures. Translumina's growth strategy likely involves expanding its presence in emerging markets, launching next-generation products, and pursuing regulatory approvals in key regions such as the U.S. and China.

Upcoming Catalysts (preview)

• 2026-12-01FDA Approval for Sirolimus-Eluting Stent70% success
• 2026-09-01Partnership or Distribution Agreement in Asia-Pacific80% success
• 2027-03-01IPO or Strategic Investment Announcement40% success